NTM Infections Market: Emerging Opportunities 馃實
Nontuberculous mycobacterial (NTM) infections are an increasing global health challenge, with rising prevalence among older adults and immunocompromised patients. In the U.S., cases surpassed 108,000 in 2023, driving a treatment market worth nearly USD 360 million. ARIKAYCE leads with strong sales, while pipeline therapies like SPR720, MNKD-101, and Epetraborole promise to reshape the landscape. Growing awareness, advanced diagnostics, and innovative therapeutics are fueling significant growth prospects through 2034.
馃憠Discover detailed insights, key companies, and future forecasts here:
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=mpr
Nontuberculous mycobacterial (NTM) infections are an increasing global health challenge, with rising prevalence among older adults and immunocompromised patients. In the U.S., cases surpassed 108,000 in 2023, driving a treatment market worth nearly USD 360 million. ARIKAYCE leads with strong sales, while pipeline therapies like SPR720, MNKD-101, and Epetraborole promise to reshape the landscape. Growing awareness, advanced diagnostics, and innovative therapeutics are fueling significant growth prospects through 2034.
馃憠Discover detailed insights, key companies, and future forecasts here:
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=mpr
0
0 Reacties
0 Aandelen